Last reviewed · How we verify
NCT05947786
Mpox Paediatric and Adolescent Clinical Study
trial in Monkey Pox in 20 participants. Status unknown.
31 July 2025
Quick facts
| Lead sponsor | PENTA Foundation |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 20 |
| Start date | 17 March 2023 |
| Primary completion | 31 July 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 6 locations across Greece, Spain |
Conditions studied
- Monkey Pox — all drugs for Monkey Pox →
- Monkeypox — all drugs for Monkeypox →
Sponsor
PENTA Foundation
Who can join
Adults 0 to 18, any sex, with Monkey Pox or Monkeypox. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this multicentre, observational study on mpox in infants, children and adolescents is to increase knowledge about mpox infection and its associated disease in infants, children and adolescents. This will be done through the development of a harmonized system that will allow standard collection of information on demographics, clinical symptoms, clinical course, treatments and outcomes. The study will be carried out in three potential phases: Phase 1 entails the rapid development of an online paediatric registry collecting anonymised data from routine care on infants, children and adolescents with laboratory-confirmed mpox virus infection. If warranted, the study will proceed to Phase 2, an enhanced observational study of children and adolescents with confirmed mpox virus infection, if more detailed prospective data collection would aid the public health response. There is also the potential to initiate Phase 3, comprising of nested sub-studies to investigate specific research questions in this population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05947786
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Monkey Pox
Currently open trials in the same condition.
- NCT07085611 — Neutralizing Power of Serum Antibodies - 2 · NA · recruiting
- NCT05627713 — Clinical and Biological Aspects of the MONKEYPOX Disease · NA · recruiting
Other PENTA Foundation trials
Trials by the same sponsor.
- NCT06482151 — Evaluation of the Prevalence of E. Coli O Serotypes in Paediatric Population With Recurrent Urinary Tract Infection · withdrawn
- NCT06139796 — Pharmacokinetics Safety and Acceptability of DRV/r for Children Living With HIV · Phase 1, PHASE2 · withdrawn
- NCT05993767 — UNIVERSAL 1: Pharmacokinetic Study of a Novel DTG/FTC/TAF Dose Ratio for Children · Phase 2 · completed
- NCT04337450 — DTG/3TC Fixed Dose Formulations for the Maintenance of Virological Suppression in Children With HIV Infection Aged 2 to · Phase 2, PHASE3 · active not recruiting
- NCT04781530 — Advanced Diagnostics for Enhanced QUality of Antibiotic Prescription in Respiratory Tract Infections in Emergency Rooms · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05947786 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by PENTA Foundation
- Last refreshed: 17 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05947786.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing